- I don't follow big pharma names like PFE as closely as I do the smaller companies in the BiotechDueDiligence coverage list, but I enjoy the free flowing format at the Goldman Sachs conference, so I thought I would post a few notes.
- See the Past Events page for the webcast link- they are still available as of 7/2/11, but I don't know how much longer that will be the case
- I was hoping to learn about PFE's perspectives on follow-on biologics (FOBs) aka biosimilars/biogenerics, but this topic was not covered at all in the webcast- the presenter was from the Oncology group and the entire discussion centered around cancer therapeutics and R&D.
- See my notes below (these are not a complete transcription by any means, just some highlights):